Media ReleasesBARD1 Life Sciences

View All BARD1 Life Sciences News


BARD1 Life Sciences Autoantibody Test Results for Ovarian Cancer Published


-- Studies performed at the University of Geneva in 2018 for the Company’s BARD1 autoantibody (AAb) test for detection of ovarian cancer published in international peer-reviewed journal Genes
-- The research-stage BARD1 AAb assay showed a predicted accuracy of 0.96 with 86% sensitivity at 95% specificity cut-off for detection of ovarian cancer in asymptomatic women compared to healthy controls
-- Similar high predicted accuracy of 0.97 for ovarian cancer was shown in high-risk women with hereditary breast and ovarian cancer syndrome (HBOC)
-- The AAb-based test is one of the approaches that BARD1 is developing for ovarian cancer to enable earlier detection, save women’s lives and avoid unnecessary surgery

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.